ABT · sample dossier
Abbott Laboratories
44/100
FreshGenerated Oct 17, 2026 · 10:00 AM UTC · 2 hours ago
This copy is frozen (Oct 17). Sign in to run the same work — filings, valuation, bull and bear, sources — on any US stock or ETF, in about 90 seconds.
Run a fresh dossierABT
EquityAbbott LaboratoriesXNYS
Decision context
HOLD
66% convictionScore 44 · Hold
A mixed picture — no strong reason to buy or sell right now.
The stock trades 13.7% below our estimate.
Current price
$104.89
Estimated value range
$90.59 – $166.20
Gap vs AlphaDog estimate
+13.7%
The stock trades at a discount, but execution uncertainties suggest waiting for a clearer catalyst.
Market context
Price
Price when available
Pick how far back the chart looks
1 month
+2.6%
3 months
+3.2%
6 months
+8.3%
1 year
-19.0%
Financial trajectory
Executive summary & thesis
Abbott Laboratories is a diversified global healthcare company with a market capitalization of $181.50B, trading at a trailing twelve-month P/E ratio of 33.84 and generating $4.23 in free cash flow per share.
- Abbott generates a solid $4.23 in trailing free cash flow per share alongside a pristine Altman Z-score of 5.00.
- Balance sheet risk is well contained with a conservative Debt/Equity ratio of 0.63 as of 2026-10-17.
- Six-month sales through 2026-06-30 grew to $23,757M from $21,500M in the prior year period (stale data older than 90 days).
- Latest quarter YoY EPS plunged -47.5% for the period ended 2026-06-30 (stale data older than 90 days), reflecting severe earnings contraction.
- Valuation remains stretched at a P/E of 33.84 and EV/EBITDA of 17.91 against a negative 1-year return of -19.0%.
- Net margin compressed to 11.6% while Piotroski F-score stands at a mediocre 5/9, confirming operating headwinds.
Things to keep in mind
- 1P/E 33.8xView source
- 2Latest quarter YoY EPS plunged -47.5% for the period ended 2026-06-30 (stale data older than 90 days), reflecting severe earnings contraction.View source
- 3Valuation remains stretched at a P/E of 33.84 and EV/EBITDA of 17.91 against a negative 1-year return of -19.0%.View source
What to watch next
What changed recently
No material changes found in the last 30 days.
Why this rating
Score 44 · Hold
Data through
FreshJun 30, 2026
Factor profile
Balanced operator
| Factor | Score |
|---|---|
| Quality | 67 out of 100 (Neutral). Business health — profits, returns, and consistency. Higher means a more durable company. |
| Growth | 0 out of 100 (Weak). How fast sales and earnings are rising. Higher means the business is expanding faster. |
| Value | 54 out of 100 (Neutral). How cheap the stock looks for what you get. Higher means a more attractive price. |
| Safety | 56 out of 100 (Neutral). Balance-sheet cushion and fewer red flags. Higher means less risk of a nasty surprise. |
| Momentum | 37 out of 100 (Weak). Recent share-price trend. Higher means buyers have been in control lately. |
Another way to look at it
A calmer look at both sides of the Abbott Laboratories story
The prevailing consensus and bear debate victor settle on a complacent 'Hold' posture, treating Abbott's 56.8% gross margin and $4.23 free cash flow per share as an unbreakable safety net.
This view drastically understates the reality that net margin has collapsed to 11.6% while return on assets has deteriorated to an anemic 5.3%. Paying a trailing P/E of 33.84 and an EV/EBITDA of 17.91 for a business suffering a -47.5% YoY quarterly EPS contraction offers virtually zero margin of safety. Consensus also dangerously relies on stale Q2 financial data older than 90 days while ignoring that quarterly net earnings were nearly sliced in half from $1,779M to $928M. With executive leadership divesting over $25.31M in stock—led by CEO Robert Ford selling $25.26M—internal stakeholders are actively exiting rather than defending this premium valuation. Investors anchoring to Abbott's pristine Altman Z-score of 5.00 are confusing long-term debt solvency with equity valuation resilience.
Consensus fixates on the 56.8% gross margin while ignoring the severe operating leverage unwind that drove net margin down to 11.6% and slashed quarterly net income from $1,779M to $928M.
Both bull and bear debaters rely heavily on quarterly results from the period ending 2026-06-30, which are stale by more than 90 days, obscuring whether the -47.5% YoY EPS contraction accelerated in Q3.
The market overlooks asset turnover and capital efficiency erosion, evidenced by a mediocre Piotroski F-score of 5/9 and an ROA of 5.3% that sits on the brink of triggering internal thesis breakers.
Extrapolating historical cash generation by citing $4.23 in trailing free cash flow per share despite operating earnings halving over the stale six-month trailing period.
Assuming price stabilization above the 200-day moving average offsets the reality that the stock is trading below its 50-day moving average and remains down 19.0% over the trailing 1-year period.
Believing that an Altman Z-score of 5.00 protects equity holders from valuation re-rating when Price/Book stands at an inflated 3.6 in the face of zero public annual revenue growth transparency.
Revisit if Net Margin falls below 11.6% (current TTM baseline).
Revisit if Debt/Equity expands above 0.63 (current TTM baseline).
Cash after investing
See whether Abbott Laboratories still makes cash after it spends to grow.
- Revisit if Net Margin falls below 11.6% (current TTM baseline).
- Revisit if Debt/Equity expands above 0.63 (current TTM baseline).
Monitor these triggers
3 checkpoints before the next earnings print
Net Margin (baseline: 11.6%) and EPS Growth YoY (baseline: -47.5% for the quarter ended 2026-06-30)
ROA falls below 5.3%, signaling structural deterioration in asset efficiency.
Gross Margin drops below 56.8%, indicating severe loss of pricing power in core healthcare segments.
Quarterly YoY EPS growth falls below -47.5%, indicating further compounding earnings degradation.
For learning and research only — not investment advice. AlphaDog doesn’t hold stocks and isn’t your financial advisor.
Run the next one yourself.
You just read a full ABT dossier — scored verdict, valuation, and both sides, with sources. Sign in to run that on a name you hold, on current filings. A free account includes 10 credits a week, 1 per fresh run.